PAVmed Adds EsoCure™ Esophageal Ablation Device with Patented Caldus™ Technology to Commercial Product Pipeline Feb 18, 2020 9:30am EST
U.S. FDA Grants PAVmed Subsidiary, Lucid Diagnostics, Breakthrough Device Designation for its EsoGuard Esophageal DNA Test Feb 11, 2020 9:30am EST
PAVmed Subsidiary Lucid Diagnostics Announces Commercial Launch of EsoGuard Esophageal DNA Test Dec 19, 2019 9:30am EST
PAVmed Reports Third Quarter 2019 Financial Results and Provides Business Update Nov 21, 2019 4:00pm EST
PAVmed Partners with Laser Technology Pioneer Dr. Jacob Wong to Develop and Commercialize Non-Invasive Laser-based Diagnostic Products Nov 14, 2019 9:30am EST
PAVmed Secures Financing up to $14 Million for Advancement of its Lead Products to Commercialization Nov 05, 2019 7:00am EST
